| Date | Title | Description |
| 28.01.2026 | Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer | Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer
Wed, Jan 28, 2026 08:30 CET Report this content
Stockholm, 28 January 2026 — Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovat... |
| 21.01.2026 | Sigrid Enters Exclusive Global Licensing and Research Collaboration to Commercialize SiPore® in Consumer Oral Health | Sigrid Enters Exclusive Global Licensing and Research Collaboration to Commercialize SiPore® in Consumer Oral Health
Wed, Jan 21, 2026 08:00 CET Report this content
Stockholm, Sweden — 21 January 2026 — Sigrid Therapeutics (Sigrid) is a Swe... |
| 07.01.2026 | Sigrid Raises USD 5 M to Accelerate Breakthrough Non-Systemic Metabolic Health Technology | Sigrid Raises USD 5 M to Accelerate Breakthrough Non-Systemic Metabolic Health Technology
Wed, Jan 07, 2026 08:00 CET Report this content
Stockholm, Sweden — January 7, 2026 — Sigrid, a Swedish innovation-driven consumer health company adva... |
| 03.11.2025 | SIGRID Expands into the U.S. Physician Channel Following Successful Pilot Program | SIGRID Expands into the U.S. Physician Channel Following Successful Pilot Program
Mon, Nov 03, 2025 08:30 CET Report this content
Stockholm, Sweden — November 3rd — SIGRID, the Swedish innovative consumer care company behind the groundbreak... |
| 18.08.2025 | Sigrid’s CarbFence™ Delivers Appetite Control, Muscle-Preserving Weight Loss, and Exceptional Safety - Positioned for Global Roll-Out | Sigrid’s CarbFence™ Delivers Appetite Control, Muscle-Preserving Weight Loss, and Exceptional Safety - Positioned for Global Roll-Out
Mon, Aug 18, 2025 08:00 CET Report this content
Stockholm, Sweden – 18th August – Sigrid Therapeutics (Sig... |
| 12.08.2025 | Sana Alajmovic to step down as CEO of Sigrid Therapeutics in early 2026 | Sana Alajmovic to step down as CEO of Sigrid Therapeutics in early 2026
Tue, Aug 12, 2025 08:00 CET Report this content
Stockholm, August 12, 2025 – Sigrid Therapeutics AB (Sigrid) announces that CEO Sana Alajmovic will leave her operationa... |
| 09.06.2025 | SIGRID’s Glucose Stabiliser Demonstrates Clinical Efficacy and U.S. Commercial Momentum Amid Growing Demand for Metabolic Health Solutions | SIGRID’s Glucose Stabiliser Demonstrates Clinical Efficacy and U.S. Commercial Momentum Amid Growing Demand for Metabolic Health Solutions
Mon, Jun 09, 2025 08:00 CET Report this content
Stockholm, Sweden – June 9, 2025. SIGRID, the Swedish... |
| 10.03.2025 | Sigrid Therapeutics Secures U.S. Market Access for SiPore® Technology in Blood Sugar and Weight Management Following Landmark SHINE Study in Prediabetes | Sigrid Therapeutics Secures U.S. Market Access for SiPore® Technology in Blood Sugar and Weight Management Following Landmark SHINE Study in Prediabetes
Mon, Mar 10, 2025 08:00 CET Report this content
Stockholm, Sweden, March 10, 2025 — Sig... |
| 05.02.2025 | Sigrid signs exclusive distribution deal with Kronans Apotek, a major Swedish pharmacy chain, for Sigrid Stabiliser | Sigrid signs exclusive distribution deal with Kronans Apotek, a major Swedish pharmacy chain, for Sigrid Stabiliser
Wed, Feb 05, 2025 08:30 CET Report this content
Follows successful e-commerce launch for innovative blood sugar management s... |
| 02.12.2024 | Sigrid Therapeutics Secures US Patent for Groundbreaking SiPore[®] Technology in Blood Sugar Management | Sigrid Therapeutics Secures US Patent for Groundbreaking SiPore[®] Technology in Blood Sugar Management
Mon, Dec 02, 2024 08:30 CET Report this content
Stockholm, Sweden, December 2, 2024. The Swedish healthtech company Sigrid Therapeutics ... |
| 05.11.2024 | A New Dawn in Diabetes Management: Sigrid Therapeutics' SiPore21® Gel | In the realm of diabetes management, a new contender is emerging. Sigrid Therapeutics has just crossed a significant milestone with its SHINE clinical trial, which evaluated the SiPore21® gel. This innovative treatment aims to provide susta... |
| 04.11.2024 | Sigrid Therapeutics Announces Last Patient Last Visit in SHINE Clinical Trial Evaluating SiPore21® Gel for Sustained Blood Sugar Control | Sigrid Therapeutics Announces Last Patient Last Visit in SHINE Clinical Trial Evaluating SiPore21® Gel for Sustained Blood Sugar Control
Mon, Nov 04, 2024 08:30 CET Report this content
Sigrid Therapeutics announces the completion of the fin... |
| 02.09.2024 | Sigrid enters strategic partnership with GetHealthy to meet growing US demand for Glucose Stabiliser as non-pharmaceutical solution to blood sugar management | Sigrid enters strategic partnership with GetHealthy to meet growing US demand for Glucose Stabiliser as non-pharmaceutical solution to blood sugar management
Mon, Sep 02, 2024 08:00 CET Report this content
US clinical nutrition for diabetes... |
| 30.07.2024 | Sigrid Therapeutics Completes Enrollment in SHINE to Evaluate SiPore21® Gel for Sustained Blood Sugar and Weight Management | Sigrid Therapeutics Completes Enrollment in SHINE to Evaluate SiPore21® Gel for Sustained Blood Sugar and Weight Management
Tue, Jul 30, 2024 08:30 CET Report this content
SiPore21® offers a non-pharmaceutical oral alternative to injectable... |
| 09.07.2024 | Biggest impact on oral health since introduction of fluoride predicted as Sigrid Therapeutics announces market readiness of SiPore® Professional Care and Consumer Range Products | Biggest impact on oral health since introduction of fluoride predicted as Sigrid Therapeutics announces market readiness of SiPore® Professional Care and Consumer Range Products
Tue, Jul 09, 2024 08:00 CET Report this content
SiPore® SMART ... |
| 30.04.2024 | Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its Clinical Trial, SHINE, to Evaluate the SiPore21® Gel for Sustained Diabetes and Obesity Control | Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its Clinical Trial, SHINE, to Evaluate the SiPore21® Gel for Sustained Diabetes and Obesity Control
Tue, Apr 30, 2024 08:30 CET Report this content
SHINE is the largest ongoing c... |
| 25.01.2024 | Sigrid Therapeutics Announces Collaboration with Cencora to accelerate commercialization of revolutionary SiPore® technology for obesity and diabetes prevention | Sigrid Therapeutics Announces Collaboration with Cencora to accelerate commercialization of revolutionary SiPore® technology for obesity and diabetes prevention
Thu, Jan 25, 2024 08:00 CET Report this content
Stockholm, Sweden – Thursday Ja... |
| 14.11.2023 | Sigrid Therapeutics Launches the Glucose Stabiliser in the U.S. | Sigrid Therapeutics Launches the Glucose Stabiliser in the U.S.
Tue, Nov 14, 2023 08:30 CET Report this content
Designed to Control Blood Sugar and Weight Without Prescriptions, The Glucose Stabiliser is a Natural Silica-Based Solution.
MIA... |
| 13.11.2023 | Sigrid launches natural drug alternative technology for weight control | The glucose control supplement uses silica mineral to prevent breakdown of carbs and fats
The assortment of obesity drugs on the market is growing at breakneck speed, with the new Zepbound just approved by the FDA, following the earlier lau... |
| 01.11.2023 | Sweden-based Sigrid Therapeutics raises USD 4 million in funding | Stockholm, Sweden-based Sigrid Therapeutics raised USD 4 million in an oversubscribed funding round. The round took place on October 31, 2023. The investment included both existing as well as new investors. The investment underlines the str... |
| 31.10.2023 | Sigrid Therapeutics Raises $4M in Funding Round | Sigrid Therapeutics, a Stockholm, Sweden-based company which specializes in obesity and diabetes management disease, raised $4M in funding.
The backers were not disclosed.
The company intends to use the funds to accelerate the commercialisa... |
| 31.10.2023 | Sigrid Therapeutics Secures $4 Million in Oversubscribed Funding Round to Tap Into Booming Obesity and Diabetes Market | Sigrid Therapeutics Secures $4 Million in Oversubscribed Funding Round to Tap Into Booming Obesity and Diabetes Market
Tue, Oct 31, 2023 08:30 CET Report this content
Both Nordic and international investors were attracted by Sigrid’s natura... |
| 09.10.2023 | Sigrid Therapeutics Announces First Patient Treated with SiPore21[®] Medical Device for Sustained Diabetes and Obesity Control | Sigrid Therapeutics Announces First Patient Treated with SiPore21[®] Medical Device for Sustained Diabetes and Obesity Control
Mon, Oct 09, 2023 08:30 CET Report this content
SiPore21® Silica "Molecular Sieves" Offer a Promising N... |
| 16.08.2023 | Major Milestone Achieved: SiPore® Data Strengthens Path to World's First Oral Medical Device for Blood Sugar Control in Prediabetics | Major Milestone Achieved: SiPore® Data Strengthens Path to World's First Oral Medical Device for Blood Sugar Control in Prediabetics
Wed, Aug 16, 2023 08:30 CET Report this content
Sigrid Therapeutics announces publication of key scientific... |
| 09.05.2023 | Sigrid Therapeutics announces appointment of distinguished Professor Iain Chapple to Scientific Advisory Board | Sigrid Therapeutics announces appointment of distinguished Professor Iain Chapple to Scientific Advisory Board
Tue, May 09, 2023 08:30 CET Report this content
World-renowned oral healthcare expert joins Sigrid’s SAB to investigate impact of... |
| 09.05.2023 | Sigrid Therapeutics announces appointment of distinguished Professor Iain Chapple to Scientific Advisory Board | Sigrid Therapeutics announces appointment of distinguished Professor Iain Chapple to Scientific Advisory Board
Tue, May 09, 2023 08:30 CET Report this content
World-renowned oral healthcare expert joins Sigrid’s SAB to investigate impact of... |
| 14.03.2023 | Sigrid Therapeutics unveils SiPore® plaque blocker at IDS 2023 | Sigrid Therapeutics unveils SiPore® plaque blocker at IDS 2023
Tue, Mar 14, 2023 08:30 CET Report this content
Sigrid Therapeutics unveils SiPore® to prevent oral pathogenic bacterial growth and plaque formation at International Dental Show... |
| 08.03.2023 | Sigrid Therapeutics reports positive results from consumer blood sugar management trial using SiPore® formulated dietary supplements in pre-diabetics, type 2 diabetics, and obese individuals | Sigrid Therapeutics reports positive results from consumer blood sugar management trial using SiPore® formulated dietary supplements in pre-diabetics, type 2 diabetics, and obese individuals
Wed, Mar 08, 2023 08:30 CET Report this content
“... |
| 22.02.2023 | Sigrid Therapeutics announces publication of scientific study showing Mesoporous Silica Particles retain their structure and function while passing through the gastrointestinal tract | Sigrid Therapeutics announces publication of scientific study showing Mesoporous Silica Particles retain their structure and function while passing through the gastrointestinal tract
Wed, Feb 22, 2023 08:30 CET Report this content
Results b... |
| 16.01.2023 | Sigrid Therapeutics raises further SEK10.6 million in oversubscribed rights issue for accelerated SiPore® commercialization | Sigrid Therapeutics raises further SEK10.6 million in oversubscribed rights issue for accelerated SiPore® commercialization
Mon, Jan 16, 2023 08:00 CET Report this content
Swedish Health and Wellbeing company on track for 2023 consumer supp... |
| 21.03.2022 | Scientific study suggests that mesoporous silica particles (MSPs) interact with the lipid digestion and absorption pathways to reduce calorific uptake | Scientific study suggests that mesoporous silica particles (MSPs) interact with the lipid digestion and absorption pathways to reduce calorific uptake
Mon, Mar 21, 2022 08:30 CET Report this content
Stockholm, March 21st, 2022: Sigrid Thera... |
| 07.03.2022 | Sigrid Therapeutics granted European patent covering the use of porous SiPore[®] silica particles as pharmaceutical or dietary active ingredients | Sigrid Therapeutics granted European patent covering the use of porous SiPore[®] silica particles as pharmaceutical or dietary active ingredients
Mon, Mar 07, 2022 08:30 CET Report this content
Stockholm, Sweden March 7, 2022. Sigrid Therap... |
| 13.12.2021 | Positive results from Sigrid Therapeutics proof-of-concept prediabetes STAR study published in Nanomedicine | Positive results from Sigrid Therapeutics proof-of-concept prediabetes STAR study published in Nanomedicine Mon, Dec 13, 2021 08:27 CET
First-in-Class Medical Device SiPore15® - based therapy significantly reduced long-term blood sugar leve... |
| 29.11.2021 | Sigrid Therapeutics’ Co-founder & CEO Sana Alajmovic named Sweden’s Female Founder of the Year 2021 | Sigrid Therapeutics’ Co-founder & CEO Sana Alajmovic named Sweden’s Female Founder of the Year 2021 Mon, Nov 29, 2021 08:00 CET
Stockholm, Sweden, November 29, 2021. Amidst fierce competition from other stars of Sweden’s booming start-u... |
| 11.11.2021 | Sigrid Therapeutics Raises $8.4M in Funding | Sigrid Therapeutics, a Stockholm, Sweden-based health-tech startup, raised $8.4M in funding.
US VC fund Joyance was joined by several Swedish family offices, including Hans and Barbara Bergström, the Mattsson family, Crosslight Partners and... |
| 10.11.2021 | Sigrid Therapeutics raises funding of $8.4M from US, Irish and Swedish investors for diabetes breakthrough | STOCKHOLM, Nov. 10, 2021 /PRNewswire/ -- Swedish healthtech startup Sigrid Therapeutics is set to prevent two of the world's biggest health challenges, type 2 diabetes and obesity with its SiPore15® powder. This vision has attracted a numbe... |
| 05.09.2019 | Sigrid Therapeutics Closes $1.6M Funding Round | Sigrid Therapeutics, a Stockholm, Sweden-based technology company developing a new class of products to improve human health, including type 2 diabetes, raised $1.6m in equity financing.
The round was led by Joyance Partners and Pär Gellerf... |
| 05.09.2019 | Top tech startup news for today, Thursday, September 5, 2019 | Good morning! Below are some of the top tech startup news for today, Thursday, September 5, 2019.
“Facebook Dating” officially launched in the US. Today, social giant Facebook officially launched a dating feature for billions of users on i... |
| - | Sigrid Therapeutics | “Safe Solution For Normalizing Blood Sugar Levels” |
| - | Sigrid Therapeutics | “SIGRID Therapeutics” |
| - | Joyance Partners Europe: Our First Year | As the first venture fund centered on “delightful moments” — those small quanta of time that bring greater joy, confidence, calm, control, and absence of anxiety or pain — Joyance Partners works with entrepreneurs ready to replace today’s s... |
